DCs can be roughly divided into two categories in ccRCC: TLS-DCs, which are characterized as HLA-DRhi CD83+ DC-LAMP+, and non-TLS-DCs (NTLS-DCs) in the tumor core, characterized as CD209+ CD83− (45). This evidence concerns the gene CD209 and neoplasm.